News brief­ing: Gilead, No­vo of­fer first glimpse at NASH cock­tail da­ta; Sean Bo­hen's can­cer biotech sets terms for $170M IPO

Gilead and No­vo Nordisk say their com­bo strat­e­gy for NASH has passed a proof-of-con­cept test, meet­ing the tol­er­a­bil­i­ty end­point across dif­fer­ent com­bi­na­tions while in­duc­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER